课题基金 / 基金详情

THREE DIMENSIONAL STRUCTURE OF PARMYOVIRUS HN

THREE DIMENSIONAL STRUCTURE OF PARMYOVIRUS HN
细小病毒 HN 的三维结构
批准号:
6626515
负责人:
ALLEN PORTNER
金额:
$18.27万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-01-01 至 2004-12-31

项目摘要

项目成果

ALLEN PORTNER的其他基金

相似基金

相关文献

中文摘要
翻译
副粘病毒是儿童呼吸道疾病的最重要原因。 我们研究的长期目标是开发预防副流感病毒(PIV)引起的呼吸道疾病的方法。 为了达到这一目标,拟议的研究将集中在建立三维结构(3D)的副粘病毒HN蛋白使用X射线晶体学。 这种蛋白质在病毒附着、穿透、病毒传播中的作用,以及作为主要中和抗原的作用,使得这种结构对于疫苗和药物开发非常重要。 使用反向遗传学,该建议还解决了PIV宿主范围和组织嗜性的决定因素。 利用遗传和生物化学方法,目的3探索PIV出芽的未知机制,这是药物干预的潜在靶点。 本提案的具体目标是:1)提案:建立HN的高分辨率3D结构。 2)问题:副流感病毒宿主范围和组织嗜性的病毒特异性决定因素是什么?3)建议:确定副粘病毒膜蛋白诱导病毒出芽的机制。 在这些目标中提出的研究,HN结构,病毒释放(出芽)和病毒传播(宿主范围决定因素)是传染周期中潜在的干预目标。
英文摘要
Paramyxoviruses are the most important cause of respiratory disease in children. The long-term objectives of our research are to develop means to prevent respiratory disease caused by parainfluenza viruses (PIV). To reach that objective, the proposed research will focus on establishing the three- dimensional structure (3D) of the paramyxovirus HN protein using x-ray crystallography. The role of this protein in virus attachment, penetration, virus spread, and as a major neutralizing antigen makes the structure important for vaccine and drug development. Using a reverse genetics, this proposal also addresses the determinants of PIV host range and tissue tropism. Using genetic and biochemical approaches aims 3 explores the unknown mechanism of PIV budding, a potential target for drug intervention. The specific aims of this proposal are 1) Proposal: Establish a high-resolution 3D structure of HN. 2) Question: What are the virus specific determinants of parainfluenza host range and tissue tropism? 3) Proposal: determine the mechanism of virus budding induced by paramyxovirus membrane proteins. The studies proposed in these aims, HN structure, virus release (budding), and virus spread (host range determinants) are potential intervention targets in the infectious cycle.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Preclinical-Clinical Paramyxovirus Vaccine Development
Preclinical-Clinical Paramyxovirus Vaccine Development
Preclinical-Clinical Paramyxovirus Vaccine Development
Preclinical-Clinical Paramyxovirus Vaccine Development
海外基金